Meeting
2023 ASCO Quality Care Symposium
Economic burden in patients (pt) with CLL/SLL (CLL) who received ≥ 2 prior lines of therapy (LOT), including a Bruton tyrosine kinase inhibitor (BTKi): A SEER-Medicare analysis.
Authors
Farrukh Tauseef Awan
University of Texas Southwestern Medical Center, Dallas, TX
Farrukh Tauseef Awan, Soham Yande, Lizzi Esterberg, Saurabh P. Nagar, Ravi K. Goyal, Masoom Priyadarshini
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A
Track
Quality, Safety, and Implementation Science,Cost, Value, and Policy,Patient Experience,Survivorship
Sub Track
Cost and Cost-Effectiveness of Care
Citation
JCO Oncol Pract 19, 2023 (suppl 11; abstr 24)
DOI
10.1200/OP.2023.19.11_suppl.24
Abstract #
24
Poster Bd #
B7
Abstract Disclosures
Similar Posters
Poster
2014 ASCO Annual Meeting
Economic burden of tyrosine kinase inhibitor (TKI) treatment failure in patients with chronic myeloid leukemia (CML).
First Author: Yaozhu J Chen
Poster
2024 ASCO Annual Meeting
Estimating the health care costs associated with receipt of lisocabtagene maraleucel: Insights from adults with mantle cell lymphoma (TRANSCEND NHL 001).
First Author: Tycel Jovelle Phillips
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Burden of illness in metastatic colorectal cancer.
First Author: Edward Neuberger
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Incidence and costs associated with clinically significant events in real-world patients with unresectable hepatocellular carcinoma on systemic therapy.
First Author: Marcus Healey